Europe rejects FDA audits under MRA (mutual recognition agreement)
This article was originally published in Clinica
Europe is taking a stronger position regarding the terms of the mutual recognition agreement (MRA) with the US in medical devices. A recent meeting of European experts decided that audits undertaken so far by the FDA in Europe in the presence of EU conformity assessment bodies (CABs) do not count as part of the MRA confidence-building programme. The reason is that the FDA did not give companies sufficient notice of the audits.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.